Chargement en cours...
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
PURPOSE: Ceftazidime–avibactam is a novel β-lactam/β-lactamase inhibitor combination recently approved in Europe and the USA for the treatment of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), among other indications. In the phase III REPROVE trial (NCT01808...
Enregistré dans:
| Publié dans: | Eur J Clin Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7223046/ https://ncbi.nlm.nih.gov/pubmed/31836928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-019-02804-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|